Kallikrein-related peptidase 10 (KLK10) expression and single nucleotide polymorphisms in ovarian cancer survival

International Journal of Gynecological Cancer

Volumn 20, Issue 4, 2010, Pages 529-536

  Batra, Jyotsna ^a   Tan, Olivia L ^a   O'Mara, Tracy ^a   Zammit, Rebecca ^a   Nagle, Christina M ^b   Clements, Judith A ^a   Kedda, Mary Anne ^a   Spurdle, Amanda B ^b  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Kallikrein related peptidase 10; Ovarian cancer; Steroid hormon regulation; Survival

Indexed keywords

KALLIKREIN RELATED PEPTIDASE 10; MESSENGER RNA; PROGESTERONE; SERINE PROTEINASE; STEROID; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BINDING SITE; BIOINFORMATICS; CANCER RISK; CANCER SURVIVAL; COMPUTER MODEL; CONTROLLED STUDY; DNA FLANKING REGION; DNA SEQUENCE; FEMALE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HORMONAL REGULATION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HAPLOTYPES; HUMANS; KALLIKREINS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGESTERONE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RESPONSE ELEMENTS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77952246142     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181d9273e     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Rosenfeld JA. Handbook of women's health: an evidence-based approach. New York, NY: Cambridge University Press; 2001.
3. Fisch MJ, Bruera E. Handbook of advanced cancer care. New York, NY: Cambridge University Press; 2003.
4. Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem. 2002;48:1198-1205.
5. Emami N, Diamandis EP. Human tissue kallikreins: a road under construction. Clin Chim Acta. 2007;381:78-84.
6. Shvartsman HS, Lu KH, Lee J, et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol. 2003;90:44-50.
7. Luo LY, Rajpert-De Meyts ER, Jung K, et al. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer. 2001;85:220-224.
8. Luo LY, Katsaros D, Scorilas A, et al. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res. 2001;7:2372-2379. (Pubitemid 32751638)
9. Luo LY, Katsaros D, Scorilas A, et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 2003;63:807-811. (Pubitemid 36231980)
10. Paliouras M, Diamandis EP. Coordinated steroid hormoneYdependent and independent expression of multiple kallikreins in breast cancer cell lines. Breast Cancer Res Treat. 2007:102; 7-18.
11. Luo LY, Grass L, Diamandis EP. Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. Clin Chim Acta. 2003;337:115-126.
12. Frith MC, Hansen U, Weng Z. Detection of cis-element clusters in higher eukaryotic DNA. Bioinformatics. 2001;17:878-889.
13. Lai J, Kedda MA, Hinze K, et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis. 2007;28:1032-1039.
14. Nagle C, Chenevix-Trench G, Spurdle AB, et al. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer. 2007;43:283-290. (Pubitemid 46123985)
15. Bharaj BB, Luo LY, Jung K, et al. Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. Prostate. 2002;51:35-41.
16. Marsh A, Healey S, Lewis A, et al. Mutation analysis of five candidate genes in familial breast cancer. Breast Cancer Res Treat. 2007;105:377-389.
17. Yousef GM, White NM, Michael IP, et al. Identification of new splice variants and differential expression of the human kallikrein 10 gene, a candidate cancer biomarker. Tumour Biol. 2005;26:227-235.
18. Michael IP, Kurlender L, Memari N, et al. Intron retention: a common splicing event within the human kallikrein gene family. Clin Chem. 2005;51:506-515.
19. Yousef GM. MicroRNAs: a new frontier in kallikrein research. Biol Chem. 2008;389:689-694.
20. Hinds DA, Stuve LL, Nilsen GB, et al. Whole-genome patterns of common DNA variation in three human populations. Science. 2005;307:1072-1079.
21. Syed V, Ulinski G, Mok SC, et al. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res. 2001;61:6768-6776.
22. Fogh J. Human tumour cells in vitro. New York, NY: Plenum Press; 1975.
23. Wolf CR, Hayward IP, Lawrie SS, et al. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer. 1987;39:695-702.
24. Tsao SW, Mok SC, Fey EG, et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res. 1995;218:499-507.
25. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-989.
26. Sidiropoulos M, Pampalakis G, Sotiropoulou G, et al. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol. 2005;26:324-336.
27. Kioulafa M, Kaklamanis L, Stathopoulos E, et al. Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. Ann Oncol. 2009;20:1020-1025.
28. Paliouras M, Diamandis EP. Androgens act synergistically to enhance estrogen-induced upregulation of human tissue kallikreins 10, 11, and 14 in breast cancer cells via a membrane bound androgen receptor. Mol Oncol. 2008;1:413-424.
29. Motohashi H, Yamamoto M. Carcinogenesis and transcriptional regulation through Maf recognition elements. Cancer Sci. 2007;98:135-139.
30. Gubbay O, Rae MT, McNeilly AS, et al. cAMP response element-binding (CREB) signalling and ovarian surface epithelial cell survival. J Endocrinol. 2006;191:275-285.